The Danish company's pioneering product portfolio includes assays for underserved disease states such as NGAL for acute kidney injury. They sell their products in more than 80 countries through diverse sales channels and partners, and their patented generic Rapid Assay Device (gRAD) is a platform technology that facilitates the fast and easy development of custom lateral flow assays. BioPorto also offers highly specific antibodies suitable for research into clinical conditions such as AKI, obesity, diabetes, innate immunity, allergy and infectious diseases.